VivoSeq
Other

Enteritis

8

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Enteritis is an early-stage landscape with 8 programs across 5 companies. The most active players are Univax Biologics Inc, Otsuka, Takeda. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

U

Univax Biologics Inc

1 program

Phase 1Otsuka logo

Otsuka

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2O

Orphanetics Pharma Entwicklungs GmbH

1 program

Phase 2Sanofi logo

Sanofi

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

7 of 9 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody222%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Unknown status2 · 20%
Not yet recruiting1 · 10%
Recruiting1 · 10%
Terminated1 · 10%
Enrolling by invitation1 · 10%

Clinical Trials

Trial Activity

10 trials

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07202598·10 enrolled
Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis
Not yet recruiting·ZZhejiang Cancer Hospital·Phase 1·NCT07175207·10 enrolled
Gegen Qinlian Tang and Probiotics for Radiation Enteritis
Enrolling by invitation·JJiujiang No.1 People's Hospital·Phase 1/2·NCT06836960·60 enrolled
The Treatment Effect of Bio-Three on Children With Enteritis
Completed·KKaohsiung Veterans General Hospital.·Phase 4·NCT01480947·80 enrolled
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients
Completed·UUnivax Biologics Inc·Phase 1·NCT00002248·40 enrolled
A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
Completed·Otsuka logoOtsuka·Phase 2·NCT02473393·43 enrolled
A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
Completed·SSoligenix·Phase 1/2·NCT01073384·16 enrolled
Vedolizumab Induction May Prevent Celiac Enteritis
Terminated·AAGA Clinical Research Associates, LLC·Phase 2·NCT02929316·1 enrolled
Therapy of Radiation Enteritis With Glutamine
Unknown status·NNanjing University School of Medicine·N/A·NCT01758783·30 enrolled
A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis
Unknown status·WWest China Second University Hospital·Phase 2·NCT05138887·366 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)